Vanda Pharmaceuticals Inc Cash Flow Conversion Efficiency
Vanda Pharmaceuticals Inc cash flow conversion efficiency. Based on the latest financial reports, Vanda Pharmaceuticals Inc (VNDA) has a cash flow conversion efficiency ratio of -0.090x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-29.42 Million) by net assets ($327.19 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Vanda Pharmaceuticals Inc (2004–2025)
Cash flow conversion efficiency of Vanda Pharmaceuticals Inc from 2004 to 2025. This chart illustrates how Vanda Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Vanda Pharmaceuticals Inc stock price today for real-time trading data and today's change.
Vanda Pharmaceuticals Inc Cash Flow Conversion Ratio Explained
Vanda Pharmaceuticals Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Vanda Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Vanda Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Also see how much is Vanda Pharmaceuticals Inc worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Central Omega Resources Tbk PT
JK:DKFT
|
0.283x |
|
Huaiji Dengyun Auto-parts Holding Co Ltd
SHE:002715
|
0.037x |
|
Turtle Beach Corporation
NASDAQ:TBCH
|
0.080x |
|
Rane (Madras) Limited
NSE:RML
|
0.032x |
|
Sarana Meditama Metropolitan
JK:SAME
|
0.011x |
|
Viking Supply Ships AB (publ)
ST:VSSAB-B
|
0.016x |
|
Bioteque
TWO:4107
|
0.036x |
|
Genesis Technology
TWO:6221
|
-0.072x |
Annual Cash Flow Conversion Efficiency for Vanda Pharmaceuticals Inc (2004–2025)
The table below shows the annual cash flow conversion efficiency of Vanda Pharmaceuticals Inc from 2004 to 2025. Review VNDA free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $327.19 Million | $-109.44 Million | -0.334x | -1043.24% |
| 2024-12-31 | $538.55 Million | $-15.76 Million | -0.029x | -224.55% |
| 2023-12-31 | $544.91 Million | $12.80 Million | 0.023x | -61.28% |
| 2022-12-31 | $527.20 Million | $31.98 Million | 0.061x | -52.30% |
| 2021-12-31 | $504.93 Million | $64.21 Million | 0.127x | +11.34% |
| 2020-12-31 | $453.27 Million | $51.77 Million | 0.114x | +2.16% |
| 2019-12-31 | $410.94 Million | $45.95 Million | 0.112x | +2.70% |
| 2018-12-31 | $275.42 Million | $29.99 Million | 0.109x | +821.36% |
| 2017-12-31 | $131.39 Million | $-1.98 Million | -0.015x | +75.54% |
| 2016-12-31 | $131.33 Million | $-8.10 Million | -0.062x | -165.93% |
| 2015-12-31 | $133.03 Million | $12.45 Million | 0.094x | +118.45% |
| 2014-12-31 | $160.82 Million | $-81.55 Million | -0.507x | +43.48% |
| 2013-12-31 | $44.12 Million | $-39.59 Million | -0.897x | +80.21% |
| 2012-12-31 | $9.90 Million | $-44.92 Million | -4.535x | -434.31% |
| 2011-12-31 | $33.47 Million | $-28.41 Million | -0.849x | -193.84% |
| 2010-12-31 | $37.73 Million | $-10.90 Million | -0.289x | -103.93% |
| 2009-12-31 | $23.03 Million | $169.34 Million | 7.353x | +836.30% |
| 2008-12-31 | $46.02 Million | $-45.96 Million | -0.999x | -61.91% |
| 2007-12-31 | $83.73 Million | $-51.64 Million | -0.617x | +68.03% |
| 2006-12-31 | $26.76 Million | $-51.62 Million | -1.929x | -233.96% |
| 2005-12-31 | $30.66 Million | $-17.71 Million | -0.578x | -6.91% |
| 2004-12-31 | $15.94 Million | $-8.61 Million | -0.540x | -- |
About Vanda Pharmaceuticals Inc
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nightt… Read more